Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trialXiaohua Wu, Linjuan Zeng, Zhongqiu Lin et al.|Nature Medicine|2024Cited by 41
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket studyLingfang Xia, Xiaohua Wu, Jin Peng et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 39